Pyzchiva® is a key biosimilar value driver for Sandoz ... access to treatment options for patients, while helping to build a more sustainable healthcare system in the US so that everyone can ...

Pyzchiva® is a key biosimilar value driver for Sandoz ... reinforces our commitment to broaden access to treatment options for patients, while helping to build a more sustainable healthcare system in ...

Pyzchiva® is a key biosimilar value driver for Sandoz ... access to treatment options for patients, while helping to build a more sustainable healthcare system in the US so that everyone can ...

Pyzchiva is a key biosimilar value driver for Sandoz ... reinforces our commitment to broaden access to treatment options for patients, while helping to build a more sustainable healthcare system in ...

Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

a lack of physician education has been one of the reasons biosimilar uptake has been slower in the US. Manufacturers can work with a commercialisation partner to build provider confidence through ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

Sharing skills across generations can build trust and communication ... alternatives to name-brand medications. The market for biosimilar medications is expected to grow over the next several ...

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's ...

Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that ...

For patients, biosimilars improve the affordability of ... As part of this collaboration, we will build two state-of-the-art manufacturing facilities, one for peptide drug substance production ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...